New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
05:03 EDTSUPNSupernus announces positive Phase 2b results on SPN-810, advances to development
Supernus Pharmaceuticals received positive top-line results from its Phase 2b study on SPN-810 for the treatment of impulsive aggression in ADHD patients. The study is a multi-center randomized, double-blind, placebo controlled clinical trial in children 6-12 diagnosed with Attention Deficit and Hyperactivity Disorder, or ADHD, and characterized by impulsive aggression that is not controlled by optimal stimulant and psychosocial treatment. A total of 121 patients were randomized in the study across placebo and three doses of SPN-810. SPN-810 was well tolerated throughout the study across all doses. The two serious adverse events that occurred were not drug related. The company will be analyzing the full data-set in depth, and subsequently planning on meeting with the FDA to discuss next steps in the development program and the design and protocol for Phase III clinical trials.
News For SUPN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
16:15 EDTSUPNSupernus sues Zydus for infringement of Trokendi patents
Subscribe for More Information
November 12, 2014
09:21 EDTSUPNOn The Fly: Pre-market Movers
Subscribe for More Information
November 11, 2014
16:38 EDTSUPNSupernus expects to be profitable in 2015
Subscribe for More Information
16:34 EDTSUPNSupernus updates progress of product candidates
Subscribe for More Information
16:33 EDTSUPNSupernus raises FY14 revenue view to $115M-$118M from $105M
FY14 consensus $104.44M. The company is reducing its cash burn guidance for the year from $5M-10M to approximately $5M, and raising its guidance for year end cash and marketable securities to approximately $85M. The company anticipates achieving cash flow break even by year end and being profitable in 2015.
16:32 EDTSUPNSupernus reports Q3 EPS 39c, consensus 36c
Reports Q3 revenue $52.5M, consensus $43.08M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use